Overview

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Status:
Not yet recruiting

Trial end date:
2026-10-31

Target enrollment:

Participant gender:

Summary

This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)

Phase:

Phase 2

Details

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborator:

West China Hospital